Breadcrumb

[A18-51] Tofacitinib (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V

Overview

Overview

Commission: Commission awarded on 2018-08-24 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Extract of dossier assessment  [PDF, 89 kB]Further documents
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact address:to the contact form
Linked projects: [A19-03] Tofacitinib (psoriatic arthritis) - Addendum to Commission A18-51
Status: Commission completed

[A18-52] Tofacitinib (Colitis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed

[A18-28] Tofacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Status: Commission completed

[A17-18] Tofacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2018-12-03 Extract of dossier assessment 89 kBPDFdownload file
2018-12-03 Dossier assessment (German version) 405 kBPDFdownload file

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


At a glance

Accompanying information

Extract of dossier assessment

  File-Icon  Tofacitinib (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V [PDF, 89 kB]

Health information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.

Tofacitinib (Xeljanz) for the treatment of joint inflammations in psoriasis (psoriatic arthritis)



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close